See FDA-approved patient labeling (Patient Information)
A statement to patients and healthcare providers is included on the product's bottle label: ALERT: Find out about medicines that should NOT be taken with VIRACEPT.
Instruction for Use
For optimal absorption, patients should be advised to take VIRACEPT with food.
Patients should be informed that VIRACEPT Tablets are film-coated and that this film-coating is intended to make the tablets easier to swallow.
If a dose of VIRACEPT is missed, patients should take the dose as soon as possible and then return to their normal schedule. However, if a dose is skipped, the patient should not double the next dose.
Adult or pediatric patients unable to swallow the tablets may dissolve the tablets in a small amount of water:
Pediatric patients unable to swallow tablets can also use the powder formulation:
Drug Interactions
VIRACEPT may interact with some drugs; therefore, advise patients to report to their healthcare provider the use of any other prescription, non-prescription medication or herbal products, including St. John's wort [see Contraindications (4), Drug Interactions (7.3), and Use in Specific Populations (8.3)].
Hepatic Impairment
Patients should be informed that VIRACEPT should not be used if there is moderate or severe hepatic impairment.
Phenylketonuria
Physicians should alert patients with phenylketonuria that VIRACEPT Oral Powder contains phenylalanine
Fat Redistribution
Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy, including PREZISTA/ritonavir, and that the cause and long-term health effects of these conditions are not known at this time
The most frequent adverse event associated with VIRACEPT is diarrhea, which can usually be controlled with non-prescription drugs, such as loperamide, which slow gastrointestinal motility.
Pregnancy Registry
Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VIRACEPT during pregnancy [see Use in Specific Populations (8.1)].
Lactation
Instruct patients with HIV-1 infection not to breastfeed because HIV-1 can be passed to the infant in the breast milk [see Use in Specific Populations (8.2)].
Females and Males of Reproductive Potential
Advise females of reproductive potential that VIRACEPT may reduce the effectiveness of estrogen-based contraceptives, and to use alternative non-hormonal contraception [see Drug Interactions (7.3), Use in Specific Populations (8.3)].
See FDA-approved patient labeling (Patient Information)
A statement to patients and healthcare providers is included on the product's bottle label: ALERT: Find out about medicines that should NOT be taken with VIRACEPT.
Instruction for Use
For optimal absorption, patients should be advised to take VIRACEPT with food.
Patients should be informed that VIRACEPT Tablets are film-coated and that this film-coating is intended to make the tablets easier to swallow.
If a dose of VIRACEPT is missed, patients should take the dose as soon as possible and then return to their normal schedule. However, if a dose is skipped, the patient should not double the next dose.
Adult or pediatric patients unable to swallow the tablets may dissolve the tablets in a small amount of water:
Pediatric patients unable to swallow tablets can also use the powder formulation:
Drug Interactions
VIRACEPT may interact with some drugs; therefore, advise patients to report to their healthcare provider the use of any other prescription, non-prescription medication or herbal products, including St. John's wort [see Contraindications (4), Drug Interactions (7.3), and Use in Specific Populations (8.3)].
Hepatic Impairment
Patients should be informed that VIRACEPT should not be used if there is moderate or severe hepatic impairment.
Phenylketonuria
Physicians should alert patients with phenylketonuria that VIRACEPT Oral Powder contains phenylalanine
Fat Redistribution
Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy, including PREZISTA/ritonavir, and that the cause and long-term health effects of these conditions are not known at this time
The most frequent adverse event associated with VIRACEPT is diarrhea, which can usually be controlled with non-prescription drugs, such as loperamide, which slow gastrointestinal motility.
Pregnancy Registry
Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VIRACEPT during pregnancy [see Use in Specific Populations (8.1)].
Lactation
Instruct patients with HIV-1 infection not to breastfeed because HIV-1 can be passed to the infant in the breast milk [see Use in Specific Populations (8.2)].
Females and Males of Reproductive Potential
Advise females of reproductive potential that VIRACEPT may reduce the effectiveness of estrogen-based contraceptives, and to use alternative non-hormonal contraception [see Drug Interactions (7.3), Use in Specific Populations (8.3)].
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.